Global Cell and Gene Therapy Market 2022-2028

March 2022 | 75 pages | ID: GE6DB423F0ACEN
Gen Consulting Company

Abstracts

Cell therapy and gene therapy aims to treat, prevent, or potentially cure diseases. It has the potential to alleviate the underlying cause of genetic diseases and acquired diseases. Projected to expand at a CAGR of 28.2% from 2022 to 2028, the global cell and gene therapy market will worth USD 21,508 million by 2028-end, according to Gen Consulting Company.

The report provides in-depth analysis and insights regarding the current global market scenario, latest trends and drivers into global cell and gene therapy market. It offers an exclusive insight into various details such as market size, key trends, competitive landscape, growth rate and market segments. This study also provides an analysis of the impact of the COVID-19 crisis on the cell and gene therapy industry.

This industry report offers market estimates and forecasts of the global market, followed by a detailed analysis of the product, therapy type, therapeutic class, and region. The global market for cell and gene therapy can be segmented by product: epicel, gendicine, imlygic, kymriah, luxturna, maci, provenge, strimvelis, tecartus, yescarta, zolgesma, zynteglo, others. The zolgesma segment captured the largest share of the market in 2021. Cell and gene therapy market is further segmented by therapy type: cell therapy, gene modified cell therapy, gene therapy. Based on therapeutic class, the cell and gene therapy market is segmented into: hematology, neurology, oncology, ophthalmology, rare diseases, others. On the basis of region, the cell and gene therapy market also can be divided into: Asia Pacific, Europe, North America, Rest of the World (RoW).

By product:

• epicel
• gendicine
• imlygic
• kymriah
• luxturna
• maci
• provenge
• strimvelis
• tecartus
• yescarta
• zolgesma
• zynteglo
• others

By therapy type:

• cell therapy
• gene modified cell therapy
• gene therapy

By therapeutic class:

• hematology
• neurology
• oncology
• ophthalmology
• rare diseases
• others

By region:

• Asia Pacific
• Europe
• North America
• Rest of the World (RoW)

The global cell and gene therapy market report offers detailed information on several market vendors, including Amgen Inc., bluebird bio, Inc., Bristol-Myers Squibb Company (BMS), Dendreon Pharmaceuticals, Inc., Gilead Sciences, Inc., Human Stem Cells Institute PJSC (HSCI), Novartis International AG, Orchard Therapeutics plc, Organogenesis Holdings Inc., Shanghai Sunway Biotech Co., Ltd., Shenzhen Sibiono GeneTech Co., Ltd. (Sibiono), Spark Therapeutics, Inc., Vericel Corporation, among others.

*REQUEST FREE SAMPLE TO GET A COMPLETE LIST OF COMPANIES

Historical & Forecast Period

This research report provides analysis for each segment from 2018 to 2028 considering 2021 to be the base year.

Scope of the Report

• To analyze and forecast the market size of the global cell and gene therapy market.
• To classify and forecast the global cell and gene therapy market based on product, therapy type, therapeutic class, region.
• To identify drivers and challenges for the global cell and gene therapy market.
• To examine competitive developments such as mergers & acquisitions, agreements, collaborations and partnerships, etc., in the global cell and gene therapy market.
• To identify and analyze the profile of leading players operating in the global cell and gene therapy market.

Why Choose This Report

• Gain a reliable outlook of the global cell and gene therapy market forecasts from 2022 to 2028 across scenarios.
• Identify growth segments for investment.
• Stay ahead of competitors through company profiles and market data.
• The market estimate for ease of analysis across scenarios in Excel format.
• Strategy consulting and research support for three months.
• Print authentication provided for the single-user license.

Contents

PART 1. INTRODUCTION

Report description
Objectives of the study
Market segment
Years considered for the report
Currency
Key target audience

PART 2. METHODOLOGY

PART 3. EXECUTIVE SUMMARY

PART 4. MARKET OVERVIEW

Introduction
Drivers
Restraints
Impact of COVID-19 pandemic

PART 5. MARKET BREAKDOWN BY PRODUCT

Epicel
Gendicine
Imlygic
Kymriah
Luxturna
Maci
Provenge
Strimvelis
Tecartus
Yescarta
Zolgesma
Zynteglo
Others

PART 6. MARKET BREAKDOWN BY THERAPY TYPE

Cell therapy
Gene modified cell therapy
Gene therapy

PART 7. MARKET BREAKDOWN BY THERAPEUTIC CLASS

Hematology
Neurology
Oncology
Ophthalmology
Rare diseases
Others

PART 8. MARKET BREAKDOWN BY REGION

Asia Pacific
Europe
North America
Rest of the World (RoW)

PART 9. KEY COMPANIES

Amgen Inc.
bluebird bio, Inc.
Bristol-Myers Squibb Company (BMS)
Dendreon Pharmaceuticals, Inc.
Gilead Sciences, Inc.
Human Stem Cells Institute PJSC (HSCI)
Novartis International AG
Orchard Therapeutics plc
Organogenesis Holdings Inc.
Shanghai Sunway Biotech Co., Ltd.
Shenzhen Sibiono GeneTech Co., Ltd. (Sibiono)
Spark Therapeutics, Inc.
Vericel Corporation
*REQUEST FREE SAMPLE TO GET A COMPLETE LIST OF COMPANIES
DISCLAIMER